Clinical Trial Detail

NCT ID NCT02309580
Title Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

lymphoma

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.